Destroy Cancer Cells Articles & Analysis
15 articles found
Cancer treatment has witnessed transformative advancements over the past few decades, notably with the emergence of CAR-T (Chimeric Antigen Receptor T-cell) therapy. This revolutionary therapy harnesses the body's immune system by genetically engineering T-cells to target and destroy cancer ...
In recent years, the field of antibody drug design has become increasingly significant in the realm of therapeutic development, driven by the need for more effective and targeted treatments for various diseases, including cancer, autoimmune disorders, and infectious diseases. Antibodies, which are proteins produced by the immune system, have the ability to specifically recognize and bind to ...
These APIs form the foundation of various therapeutic strategies aimed at inhibiting or destroying tumor cells in the human body. The classification of anti-tumor APIs often falls into four main types: chemotherapy drugs, targeted therapy drugs, immunotherapy drugs, and hormone therapy drugs. ...
They are adept at identifying and destroying infected or cancerous cells. However, their natural capacity may not always be sufficient to combat complex diseases. ...
Gene delivery in cancer treatment involves the use of viral or non-viral vectors to deliver therapeutic genes into cancer cells. These approaches allow the targeted delivery of genes that can inhibit tumor growth or enhance the immune system's capability to recognize and destroy cancer cells. One ...
Cancer is a daunting diagnosis; however, the rapid advancements in oncology are continuously perfecting patient outcomes and quality of life. Among the groundbreaking developments, cancer vaccines are a promising frontier1. These vaccines are transforming how we approach cancer treatment, leveraging the body's immune system to fight malignancies more effectively. To grasp how cancer vaccines ...
Recently, in the renowned academic journal Nature Medicine, the Kimmel Cancer Center at Johns Hopkins University published Phase 2 clinical results regarding enoblituzumab, a monoclonal antibody targeting B7-H3, for the treatment of prostate cancer. The results demonstrate that enoblituzumab can successfully induce the body's anti-cancer activity, showing favorable therapeutic efficacy and safety ...
Gold nanocages refer to the hollow gold nanostructures with porous walls that were developed by Sun and Xia and Chen et al. in the early 2000s. The hollow and porous structures are synthesized by the galvanic replacement between silver nanocubes and chloroauric acid in aqueous solution. By controlling the size of nanocube templates, the monodispersed cubic nanocages are readily obtained with ...
For example, matrix-targeting ADC drugs have the potential to cause cancer cell death by reducing the concentration of growth factors produced by matrix-resident cells. ...
The researchers expose us to a radically different way of thinking in this article: instead of working on T cells, they focus on changing cancer cell antigens. They employed antibodies to deliver viral antigens to the tumor location and trigger virus-specific T lymphocytes to target cancer cells, ...
Heart failure, liver disease, and kidney failure are just a few of the major conditions that can result from cardiac fibrosis. The FDA approved CAR-T cell therapy, also known as chimeric antigen receptor T-cell therapy, as the first CAR-T cell therapy to be marketed for the treatment of leukemia in 2017, ushering in a new age of CAR-T ...
Traditional immunotherapies, such as immune-activating cytokine therapy, checkpoint inhibition, engineered T-cells, etc., do not directly destroy cancer cells, but completely depend on activating the immune system. ...
Considerable investment into cancer research has led to the development of remarkable new therapies, which have greatly improved therapeutic outcome for the countless individuals diagnosed with cancer. Until recently, almost all therapies that were granted clinical approval were small molecules. However, biotechnological advances in the last several decades have made it possible to develop ...
Chimeric antigen receptor T-cells (CAR-T) are one of the first clinically approved therapies to take full advantage of the most significant advancements in immunology and genetic engineering. The resulting therapeutics have been shown to produce remission rates exceeding 80% in patients with CD19+ B-cell lymphoma, making them nothing short of remarkable [1]. Unfortunately, CAR-T cells seem ...